The UK and US have finalized a important trade agreement that will maintain no duties on British medicine shipments going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to raise spending on pharmaceuticals through the NHS. This commitment guarantees that duties on these vital goods will stay at nothing for a timeframe of three years.
This agreement comes after recent threats to hike duties on branded pharmaceutical imports, with increases mentioned reaching double the cost.
"This agreement with the United Kingdom reinforces the international landscape for innovative medicines and brings much-needed fairness to American-British pharmaceutical trade," a release declared.
Trade Impact
Drugs are one of the UK's biggest exports to the US, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the year leading up to last September, the UK shipped drugs valued at billions to the US. This figure represented nearly one-fifth of British export trade in that span.
"This deal secures work, stimulates funding and facilitates the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The pact includes several specific changes from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Last year, rebates were more than 20%.
Recent Tensions
The deal takes place against a protracted row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
These tensions were exacerbated by claims that American customers were paying significantly more for the same drugs than consumers in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been announced toward projects in the United States.
One official stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
